Markets:

Overview

News

Currencies

International

Treasuries

SpringWorks Therapeutics, Inc. - common stock (NQ:SWTX)

46.99 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about SpringWorks Therapeutics, Inc. - common stock

< Previous 1 2 3 Next >

Legendary Investor Stanley Druckenmiller Made Huge AI And Chipmaker Bets In Q2 — Here's What He Knows That You Don't ↗

August 18, 2025

See Stanley Druckenmiller's Q2 13F filing. Duquesne adds Microsoft and big banks, cuts Coupang, and makes a bullish bet on the US market.

Via Benzinga

Topics Artificial Intelligence

California Rep. Gilbert Ray Cisneros Sold Over $28K Worth of SpringWorks Therapeutics Inc Ordinary Shares Stock: Here's What You Should Know ↗

July 11, 2025

Via Benzinga

Analyst Expectations For SpringWorks Therapeutics's Future ↗

April 28, 2025

Via Benzinga

Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion ↗

April 28, 2025

Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for rare tumor treatments and immediate revenue growth.

Via Benzinga

Assessing SpringWorks Therapeutics: Insights From 6 Financial Analysts ↗

February 24, 2025

Via Benzinga

Earnings Scheduled For February 20, 2025 ↗

February 20, 2025

Via Benzinga

Smart Money Is Betting Big In SWTX Options ↗

February 10, 2025

Via Benzinga

SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout ↗

April 24, 2025

After the closing bell, Merck said the two parties were discussing a deal at around $47 per share.

Via Stocktwits

No Quick Fix For This Market ↗

March 23, 2025

Despite the pullback, we have found numerous opportunities which we discuss in this video using technical analysis.

Via Talk Markets

Topics Stocks / Equities

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week ↗

March 16, 2025

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.

Via Stocktwits

SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest? ↗

March 10, 2025

Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.

Via Stocktwits

10 Health Care Stocks Whale Activity In Today's Session ↗

February 27, 2025

Via Benzinga

Top 3 Health Care Stocks You May Want To Dump In February ↗

February 20, 2025

Via Benzinga

SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect ↗

February 20, 2025

Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.

Via Stocktwits

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗

February 16, 2025

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 14, 2025

Via Benzinga

SpringWorks Therapeutics Secures FDA Approval For Second Cancer Drug ↗

February 12, 2025

SpringWorks' Gomekli wins FDA approval for NF1-related tumors, showing strong efficacy in trials. U.S. launch expected in two weeks, with EU review ongoing.

Via Benzinga

Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics ↗

February 11, 2025

Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology business amid patent expirations and competition.

Via Benzinga

Topics Intellectual Property

Crude Oil Rises Sharply; Manhattan Associates Shares Slide ↗

February 10, 2025

Via Benzinga

Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets ↗

February 10, 2025

Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.

Via Stocktwits

Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss ↗

February 10, 2025

Via Benzinga

Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday ↗

February 10, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 27, 2025

Via Benzinga

SpringWorks Therapeutics Stock Sees RS Rating Jump To 86 ↗

January 13, 2025

On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.

Via Investor's Business Daily

Plug Power, Capri And Frontline Are Among Top Mid Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio? ↗

January 12, 2025

These mid-cap stocks had impressive gains last week, including Inari Medical, Unifirst Corporation, and Walgreens. Are they in your portfolio?

Via Benzinga

SpringWorks Therapeutics Stock Gets A RS Rating Lift ↗

January 08, 2025

The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.

Via Investor's Business Daily

SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗

August 21, 2024

A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance.

Via Investor's Business Daily

SWTX Stock Earnings: SpringWorks Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 07, 2024

SWTX stock results show that SpringWorks Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

SWTX Stock Earnings: SpringWorks Therapeutics Meets EPS, Beats Revenue for Q1 2024 ↗

May 02, 2024

SWTX stock results show that SpringWorks Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.